Matrix metalloproteinase-9 expression in the normal mucosa-adenoma- dysplasia-adenocarcinoma sequence of the colon

Pathology and Oncology Research

Volumn 14, Issue 1, 2008, Pages 31-37

  Herszényi, László ^a   Sipos, Ferenc ^a   Galamb, Orsolya ^b   Solymosi, Norbert ^a   Hritz, István ^a   Miheller, Pál ^a   Berczi, Lajos ^a   Molnár, Béla ^a,b   Tulassay, Zsolt ^a,b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Adenoma; Colorectal cancer; Dysplasia; Matrix metalloproteinase 9; Polymerase chain reaction

Indexed keywords

GELATINASE B; PARAFFIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER TISSUE; CELL DIFFERENTIATION; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DYSPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STROMA CELL;

ADENOCARCINOMA; ADENOMA; AGED; ANALYSIS OF VARIANCE; COLON; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 49349085163     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12253-008-9004-5     Document Type: Article

References (62)

1. AC Berger ER Sigurdson T LeVoyer 2005 Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes J Clin Oncol 23 8706 8712
2. H Liang XN Wang BG Wang 2006 Prognostic factors of young patients with colon cancer after surgery World J Gastroenterol 12 1458 1462
3. P Fuszek HC Horváth G Speer 2006 Location and age at onset of colorectal cancer in Hungarian patients between 1993 and 2004. The high number of advanced cases supports the need for a colorectal cancer screening program in Hungary Anticancer Res 26 531 537
4. LA Liotta WG Stetler-Stevenson 1991 Tumor invasion and metastasis: an imbalance of positive and negative regulation Cancer Res 51 S5054 S5059
5. K Dano N Behrendt G Hoyer-Hansen 2005 Plasminogen activations and cancer Thromb Haemost 93 676 681
6. L Herszényi M Plebani P Carraro 1997 Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer Am J Gastroenterol 92 843 847
7. M Plebani L Herszényi R Cardin 1995 Cysteine and serine proteases in gastric cancer Cancer 76 367 375
8. M Plebani L Herszényi P Carraro 1997 Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role Clin Exp Metastasis 15 418 425
9. L Herszényi M Plebani P Carraro 1999 The role of cysteine and serine proteases in colorectal cancer Cancer 86 1135 1142
10. F Farinati L Herszényi M Plebani 1996 Increased levels of cathepsin B and L, urokinase-type plasminogen activator and inhibitor type-1 as an early event in gastric carcinogenesis Carcinogenesis 17 2581 2587
11. LL Johnson R Dyer DJ Hupe 1998 Matrix metalloproteinases Curr Opin Chem Biol 2 466 471
12. I Stamenkovic 2003 Extracellular matrix remodelling: the role of matrix metalloproteinases J Pathol 200 448 464
13. AG Mysliwiec DL Ornstein 2002 Matrix metalloproteinases in colorectal cancer Clin Colorectal Cancer 1 208 219
14. H Sato Y Okada M Seiki 1997 Membrane-type metalloproteinases (MT-MMPs) in cell invasion Thromb Haemost 78 497 500
15. AR Nelson B Fingleton ML Rothenberg 2000 Matrix metalloproteinases: biologic activity and clinical implications J Clin Oncol 18 1135 1149
16. CF Sier FJ Kubben S Ganesh 1996 Tissue levels of matrix metalloproteinase MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinomas Br J Cancer 74 413 417
17. Y Matsuyama S Takao T Aikou 2002 Comparison of matrix metalloproteinases expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas J Surg Oncol 80 105 110
18. L Herszényi I Hritz I Pregun 2007 Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in the esophageal carcinogenesis World J Gastroenterol 13 676 682
19. K Saito S Takeha K Shiba 2000 Clinicopathologic significance of urokinase receptor- and MMP-9 positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogeneous metastasis Int J Cancer 86 24 29
20. HM Collins TM Morris SA Watson 2001 Spectrum of matrix metalloproteinase expression in primary metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane-type-1-matrix metalloproteinase Br J Cancer 84 1664 1670
21. E Roeb CG Dietrich R Winograd 2001 Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma: differential activity of matrix metalloproteinase-9 Cancer 92 2680 2691
22. ET Waas RM Lomme J deGroot 2002 Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer Br J Cancer 86 1876 1883
23. D Murray M Morrin S McDonnel 2004 Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism Anticancer Res 24 489 494
24. TD Kim KS Song G Li 2006 Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer BMC Cancer 6 211
25. G Thiéfin A Dupont PJ Guillou 2007 Beneficial influence of microsatellite instability on gelatinase-tissue inhibitors of metalloproteinase balance in colorectal cancer Anticancer Res 27 583 588
26. TC Sardinha JJ Nogueras H Xiong 2000 Membrane-type 1 matrix metalloproteinase mRNA expression in colorectal cancer Dis Colon Rectum 43 389 395
27. S Papadopoulou A Scorilas N Arnogianaki 2001 Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa Tumour Biol 22 383 389
28. MF Leeman JA McKay GI Murray 2002 Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer J Clin Pathol 55 758 762
29. M Pesta L Holubec O Topolcan 2005 Quantitative estimation of matrix metalloproteinase 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples Anticancer Res 25 3387 3391
30. ZS Zeng Y Huang AM Cohen 1996 Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9 J Clin Oncol 14 3133 3140
31. EA Baker FG Bergin DJ Leaper 2000 Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging Br J Surg 87 1215 1221
32. S Curran SR Dundas J Buxton 2004 Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers Cancer Res 10 8229 8234
33. M Illemann N Bird A Majeed 2006 MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases Mol Cancer Res 4 293 302
34. I Kirman S Jain V Cekic 2006 Altered plasma matrix metalloproteinase-9/ tissue inhibitor of matrix (corrected) metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer Surg Endosc 20 482 486
35. H Islekel G Oktay C Terzi 2007 Matrix metalloproteinase-9, -3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables Cell Biochem Funct 25 433 441
36. CE Dukes 1932 The classification of cancer of the rectum J Pathol 35 323 332
37. RB Turnbull K Kyle FR Watson 1967 Cancer of the colon: the influence of the no-touch isolation on the survival rates Ann Surg 166 420 427
38. F Sipos O Galamb L Herszényi 2007 Elevated insulin-like growth factor 1 receptor, hepatocyte growth factor receptor and telomerase expression in mild ulcerative colitis Scand J Gastroenterol 23 1 10
39. EJ Bernhard SB Gruber RJ Muschel 1994 Direct evidence linking expression of matrix metalloproteinase 9 (92kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells Proc Natl Acad Sci USA 91 4293 4297
40. C Legrand C Gilles JM Zahm 1999 Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodelling J Cell Biol 146 517 529
41. Y Tang MT Nakada P Kesavan 2005 Extracellular matrix metalloproteinase inducer stimulates tumor angioegenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases Cancer Res 65 3193 3199
42. OR Mook WM Frederiks CJF Van Noorden 2004 The role of gelatinases in colorectal cancer progression and metastasis Biochim Biophys Acta 1705 69 89
43. ZS Zeng JG Guillem 1996 Colocalisation of matrix metalloproteinase-9-mRNA and protein in human colorectal stromal cells Br J Cancer 74 1161 1167
44. WJ Lubbe ZY Zhou W Fu 2006 Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer Clin Cancer Res 12 1876 1882
45. Q Gao MJ Meijer FJ Kubben 2005 Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases Dig Liver Dis 37 584 592
46. BC McKaig D McWilliams SA Watson 2003 Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease Am J Pathol 162 1355 1360
47. K Nosho M Yoshida H Yamamoto 2005 Association of Ets-related transcriptional E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis Carcinogenesis 26 892 899
48. T Rath M Roderfeld J Graf 2006 Enhanced expression of MMP-7 and MMP 13 in inflammatory bowel disease: a precancerous potential? Inflamm Bowel Dis 12 1025 1035
49. K Harada S Hiraoka J Kato 2007 Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features Br J Cancer 97 1425 1431
50. K Hashimoto Y Shimizu Y Suehiro 2008 Hypermethylation status of APC inversely correlates with the presence of submucosal invasion in laterally spreading colorectal tumors Mol Carcinog 47 1 8
51. F Model N Osborn D Ahlquist 2007 Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease Mol Cancer Res 5 153 163
52. MN Holten-Andersen IJ Christensen HJ Nielsen 2002 Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer Clin Cancer Res 8 156 164
53. M Pesta O Topolcan L Holubec Jr 2007 Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples Anticancer Res 27 1863 1867
54. C Frederiksen J Lykke IJ Christensen 2007 Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer Scand J Clin Lab Invest 67 545 552
55. Y Ogata K Matono T Sasatomi 2005 The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer Cancer Chemother Pharmacol 57 577 583
56. NM Sorensen P Byström IJ Christensen 2007 TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid Clin Cancer Res 13 4117 4122
57. LM Coussens B Fingleton LM Matrisian 2002 Matrix metalloproteinase inhibitors and cancer-Trials and tribulations Science 295 2387 2392
58. P Vihinen R Ala-Aho VM Kahari 2005 Matrix metalloproteinases as therapeutic targets in cancer Curr Cancer Drug Targets 5 203 220
59. M Burg-Roderfeld M Roderfeld S Wagner 2007 MMP-9-hemopexin domain hampers adhesion and migration of colorectal cancer cells Int J Oncol 30 985 992
60. M Pavlaki S Zucker 2003 Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials Cancer Metastasis Rev 22 177 203
61. S van Smarle A van Vliet F Sollie 2005 Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers Int J Pharmacol Ther 43 282 293
62. AA Chiappori SG Eckhardt R Bukowski 2007 A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors Clin Cancer Res 13 2091 2099